VectorY Raises $83.5M to Push a TDP-43 Gene Therapy Through ALS

On a Tuesday in September, Leonard van den Berg watched a patient at UMC Utrecht receive an infusion meant to turn their own motor neurons into antibody factories. Van den Berg, who chairs the Dutch ALS centre, called it the first clinical study to address TDP-43 pathology directly. He was not announcing a cure. He was marking a delivery mechanism.

Two months later, on 11 November, VectorY Therapeutics closed €74.5 million ($83.5 million) to carry that mechanism through the final readout of PIONEER-ALS, its Phase 1/2 trial. The Amsterdam- and Boston-based company has raised about €234.5 million since its 2021 seed round, according to European Biotechnology. The new money is not a Series B. It is a runway extension for one readout and a platform the company wants to point at Huntington's disease next.

What the vector actually carries

VTx-002 is a first-in-class vectorized antibody. An engineered adeno-associated virus carries genetic instructions into cells of the central nervous system, which then produce a therapeutic antibody themselves. The antibody is designed to recognise the aggregated form of TDP-43, a protein that clumps in motor neurons in up to 97% of ALS patients.

That percentage is the commercial argument. Gene-specific ALS therapies address small slices of the population; tofersen, approved in 2023, works for the roughly 2% of patients with an SOD1 mutation. A TDP-43-directed approach, if it works, speaks to almost everyone else.

The delivery model matters as much as the target. Conventional antibody drugs for the brain require repeated dosing and a way across the blood-brain barrier. VectorY's single administration is designed to produce sustained, local antibody expression. One injection, then the patient's cells keep manufacturing the drug.

Six years, compressed

CHRONICLE: VectorY Therapeutics
────────────────────────────
2021  ·  €31 million seed round
2023  ·  €129 million Series A, VTx-002 still preclinical
FEB 2026  ·  first participant dosed in PIONEER-ALS
APR 2026  ·  U.K. MHRA authorisation and EMA approval to run the trial
SEP 2026  ·  enrolment expanded from 12 to 36 participants
NOV 2026  ·  €74.5 million extension, including a €30 million EIB loan
NEXT  ·  final PIONEER-ALS readout, no date disclosed

The September expansion is the detail to hold onto. VectorY tripled the trial from 12 to 36 participants before receiving any patient efficacy data. The company attributed the move to rapid enrolment and fast site activation. Both can be true. It also means the study is now larger than a pure safety run, which raises the chance that a secondary endpoint produces something worth arguing about.

The 40% that is a loan

Roughly two-fifths of the package is a €30 million convertible loan from the European Investment Bank, backed by the European Commission's InvestEU programme. The rest comes from a syndicate that includes new investors Angelini Ventures and Invest-NL, alongside returning backers Forbion, EQT Life Sciences, MRL Ventures, Insight Partners, BioGeneration Ventures, Eli Lilly and the ALS Investment Fund.

That structure changes what the round means. A convertible loan is a bet with a floor and a delay. The EIB is buying optionality on a platform, not casting a verdict on a Phase 1/2 readout. Dealroom ranks the loan in the top 3% of all-time convertible rounds for Dutch health companies by amount. Impressive as a financing fact. Weak as clinical evidence.

It will support the advancement of VTx-002 through important clinical milestones, including the final readout of PIONEER-ALS.— Jim Scibetta, chief executive, VectorY Therapeutics

Public money arriving this early is a signal about European biotech policy, not about TDP-43 biology. Brussels wants domestic clinical-stage assets. VectorY needs capital that does not demand a valuation reset. Both sides get something. Neither side has seen efficacy data.

The graveyard is the context

ALS has absorbed a lot of optimism. Riluzole, approved in 1995, bought patients an average of two to three extra months. Edaravone slowed decline in a narrow subgroup in 2017. Tofersen reached the market in 2023 for a single genetic slice of the disease. For most patients, the pipeline has been quiet for decades.

This year alone, Otsuka and Ionis reported positive Phase 3 results for ulefnersen in FUS-ALS, a rare inherited form. Weeks earlier, Novartis halted its ALS candidate VHB937 after a mid-stage failure. The field can produce a win and a write-off in the same month.

As we wrote in November, when Specific Biologics raised $35 million to delete the ALS repeat, the field is splitting into distinct bets: replace a gene, edit a repeat, or instruct cells to make their own drug. VectorY is in the third camp, and its target is the widest of the three.

What would count as a signal

PIONEER-ALS is open-label and dose-escalating, with two dose levels across sites in the U.S., Europe and the U.K. The primary objective is safety, tolerability and pharmacokinetics. The exploratory endpoints are where the interesting data lives: neurofilament light chain, a protein that rises when nerve cells are damaged, plus TDP-43 pathway biomarkers and clinical measures such as ALSFRS-R, slow vital capacity, hand-held dynamometry and survival.

A falling NfL trend in a small open-label cohort is not proof. It is a reason to run a controlled trial. VectorY has not disclosed when the final readout will arrive, which is itself a useful signal: the company is not promising a date it cannot control.

The harder question is manufacturing and durability. A single administration that instructs cells to produce an antibody for years has to keep producing it, in the right place, at the right level, without triggering an immune response against the vector or the antibody. Those are engineering problems before they are clinical ones. VectorY's platform claim rests on them.

The company has not said how long the vector's expression lasts, which is the number that would separate a durable therapy from a slow-release one.

For now, the €74.5 million buys time and a larger dataset. It does not buy an answer. The ALS community has learned to tell the difference, and so should the investors who just wrote the cheques.